Found 12 clinical trials
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
- 0 views
- 29 May, 2022
- 1 location
Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis
Tinea Pedis infected the feet of about 20-25% of the world population. Tinea Pedis is a fungal infection of the feet and it is easily spread. Oral therapy is usually used for chronic conditions or when topical treatment has failed. The aim of this study is to prove the antifungal …
- 7 views
- 23 Feb, 2022
- 1 location
Multi-center Study to Assess Safety, Tolerability and Efficacy of MBN-101 in Patients With Moderate/Severe DFI
This is a randomized, open label, controlled study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied MBN-101 in hospitalized patients with diabetic foot
- 0 views
- 27 Jun, 2022
- 1 location
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks …
- 37 views
- 10 Oct, 2021
- 22 locations
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of …
- 0 views
- 22 Oct, 2021
- 23 locations
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
process in Type 2 diabetics having foot ulcers classified as being Wound, Ischemia, foot Infection (WIfI) stage 2 or lower. The criterion reference measure of diabetic foot ulcer wound healing is be the
- 0 views
- 24 May, 2022
Optimal Antibiotics for Operated Diabetic Foot Infections
Diabetic foot problems, especially infections (DFI), require multiple resources including iterative surgeries and amputations, long-lasting antibiotic therapies, education, off-loading and eventually revascularization and appropriate foot-ware. Treatment is complicated, multidisciplinary, and marked with a high risk of recurrences. This is a retrospective and prospective cohort with side studies of pathologies and …
- 0 views
- 23 Apr, 2022
- 1 location
Ceftriaxone as Home IV for Staph Infections
Patients who are admitted to hospital with serious infections, such as those in bone, joints or spine, require a long course of intravenous (IV) antibiotics. After an initial treatment course in hospital or through a dedicated outpatient antibiotic program many patients can complete their treatment course at home. Such infections …
- 42 views
- 16 Feb, 2022
- 2 locations
Implementation of Telemedicine for Patient With Lower Extremity Wounds
The objective of this study is to determine if patients with lower extremity wounds in rural communities who undergo specialty referral through telemedicine have expedited care compared to patients who are treated through standard in person referral.
- 57 views
- 16 Mar, 2021
- 1 location
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections
This will be a prospective, open-label, two-center study to assess the safety of omadacycline use in the treatment of hospitalized subjects with moderate to severe DFI who are at a high risk for development of CDI, AKI, and/or resistant pathogens compared to retrospective controls. Prospective enrollment will be continued until …
- 0 views
- 26 Nov, 2021
- 2 locations
- 1
- 2